论文部分内容阅读
目的观察和评价重组人γ-干扰素(IFN-γ)辅助治疗耐多药结核病(MDR-TB)的疗效。方法将60例MDR-TB患者采用计算机随机分组方法分为治疗组、对照组各30例。采用3SpPaZETH/9SPPE方案治疗(Sp:司帕沙星,Pa:力克菲蒺,Z:吡嗪酰胺,E:乙胺丁醇,TH:丙硫异烟胺),治疗组在加强期加用IFN-γ雾化吸入2个月。结果共有57例患者完成疗程。治疗组28例,痰菌阴转率82.1%,对照组29例,痰菌阴转率58.6%(P<0.05),治疗组病灶显效率92.9%,优于对照组(P<0.01)。治疗组治疗3个月时CD4、CD4/CD8较对照组提高(P<0.05)。IFN-γ雾化吸入无严重不良反应。结论重组人γ-干扰素可辅助治疗耐多药结核病,是一种安全、可靠的生物制剂。
Objective To observe and evaluate the efficacy of recombinant interferon gamma (IFN-γ) in the treatment of multidrug-resistant tuberculosis (MDR-TB). Methods Sixty MDR-TB patients were randomly divided into treatment group and control group with 30 cases in each group. The treatment group was treated with 3SpPaZETH / 9SPPE regimen (sp: sparfloxacin, Pa: leflunomide, Z: pyrazinamide, E: ethambutol, TH: -γ aerosol inhalation for 2 months. Results A total of 57 patients completed the course of treatment. The treatment group, 28 cases, sputum negative conversion rate of 82.1%, control group of 29 cases, sputum negative conversion rate of 58.6% (P <0.05), the treatment group was significantly higher efficiency of 92.9%, better than the control group (P <0.01). CD4 and CD4 / CD8 in the treatment group were higher than those in the control group at 3 months (P <0.05). IFN-γ inhalation no serious adverse reactions. Conclusion Recombinant human interferon-γ can be used as a safe and reliable biological agent to treat MDR-TB.